You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Skip Main Navigation
Skip All Navigation
Albany Law Journal of Science and Technology
FDAs Oversight of the Promotion of Drugs for Off-Label Uses
19.0000000000000 ALB. L.J. SCI. & TECH. 627 (2009)
The Government Accountability Office, GAO, which you may be familiar with, is the investigative arm of Congress and most of our work comes at the request of members of Congress. In July of last year we issued a report on the FDA’s oversight of the promotion of drugs for off-label uses. The report originated as a request from Senator Grassley, a Senator from Iowa who is very interested in FDA issues, and who was then the Chair of the Senate Finance Committee.